Conclusions and Summary
Using two different experimental systems we were able to define two distinct regions in the sequence of gag proteins of HIV which function in the assembly of structural components of the virus and particle morphogenesis. Since assembly could be inhibited by addition of synthetic non-toxic peptide compounds, a new group of antiviral agents may be developed. This approach represents a completely new inhibitory principle. Besides irreversibly blocking the synthesis of progeny virus, this class of peptidomimetic inhibitors might be of special interest since non-infectious particles are released which should still be capable of stimulating the immune system and helping to induce an improved immune status. Those effects have been observed when mice were vaccinated with Rauscher murine leukemia virus and treated simultaneously with zidovudine and interferon-α [69].
Besides the development of antiviral compounds active viral protein regions actively involved in morphogenesis may be developed for applications in gene therapy using assembly defective gag proteins to negatively influence virus production via transdominant-negative effects.
Article PDF
Similar content being viewed by others
References
Barré-Sinoussi F, Cherman JC, Rey F (1983) Isolation of a T-lymphocyte retrovirus from a patient with risk for acquired immunodeficiency syndrome. Science 220: 868–871
Popovic M, Sarngadharan MG, Reed E, Gallo RC (1984) A method for detection, isolation and continuous production of cytopathic human T-lymphotropic retroviruses of the HTLV family (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497–500
Gheysen D, Jacobs E, de Forestra F, Thiriart C, Francotte M, Thine SD, de Wilde M (1989) Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59: 103–112
Gelderblom HR, Özel M, Pauli G (1989) Morphogenesis and morphology of HIV: structure-function relations Arch Virol 106: 1–13
Henderson LE, Bowers MA, Sowder RC, Serabyn SA, Johnson DG, Bess JW, Arthur LO, Bryant D, Fenselen D (1992) Gag-proteins of the highly replicative MN strain of human immunodeficiency virus type 1: postranslational modifications, proteolytical processings and complete amino acid sequences. J Virol 66: 1856–1865
Henderson LE, Sowder RC, Copeland TD, Oroszlan S, Beneveniste RE (1990) Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virious. J Med Primatol 19: 411–419
Veronese FD, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG (1988) Biochemical and immunological analysis of human immunodeficiency virus gag-gene products p17 and p24. J Virol 62: 795–801
Göttlinger HG, Sodroski JG, Haseltine WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86: 5781–5785
Yuan X, Yu X, Lee TH, Essex M (1993) Mutations in the N-terminal region of human immunodeficiency type 1 matrix protein blocks intracellular transport of the gag-precursor. J Virol 67: 6387–6394
Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP (1993) Human immunodeficiency virus type 1 gag-protein binds to cyclophillins A and B. Cell 73: 1067–1078
Jacks T, Power M, Masiarz FR, Luciv PA, Barr PJ, Varmus HE (1988) Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331: 280–283
Wilson W, Braddock M, Adams SE, Rathja PD, Kingsman SM, Kingsman AJ (1988) HIV expression strategies: ribosomal frameshifting is directed by a short sequence both in mammalian and yeast systems. Cell 55: 1159–1169
Walter P, Gilmore R, Blobel G (1984) Protein translation across the endoplasmatic reticulum. Cell 38: 5–8
Kosarsky K, Penman M, Basiripour L, Haseltine W, Sodroski J, Krieger M (1989) Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. J AIDS 2: 163–169
Ranajit P, Hoke GM, Sarngadharan MG (1989) Role of oligosaccharides in the processing and maturation of envelope glycoproteins of HIV-1. Proc Natl Acad Sci USA 86: 3384–3388
Dewar RL, Vasudevachari MB, Natarajan V, Salzman NP (1989) Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effect of monensin on glycosylation and transport. J Virol 63: 2452–2456
Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD (1988) Biosynthesis, cleavage and degradation of the human immunodeficiency virus type 1 gp160. Proc Natl Acad Sci USA 85: 9580–9584
Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Gartem W (1992) Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein 160. Nature 360: 385–391
Aldorini A, Young RA (1990) Mutations of RNA and protein sequences involved in HIV-1 packaging result in production of non-infectious virus. J Virol 64: 1920–1926
Gorelik RJ, Nigida SM, Bess JW, Arthur LO, Henderson LE, Rein A (1990) Non-infectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol 64: 3207–3211
South TL, Blake PR, Hare DR, Summers MF (1991) C-terminal retroviral-type Zink finger domain from HIV-1 nucleocapsid protein structurally similar to the N-terminal Zink finger domain. Biochemistry 30: 6342–6349
Danull J, Surovoy A, Jung G, Moelling K (1994) Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J 13: 1525–1533
Dorfman T, Luban J, Goff SP, Haseltine WA, Göttlinger HG (1993) Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol 67: 6159–6169
Dorfman T, Mammano F, Haseltine WA, Göttlinger HG (1994) Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 68: 1689–1696
Yu X, Yuan X, Matsuda Z, Lee T-H, Essex M (1992) The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope proteins into mature virus. J Virol 66: 4966–4971
Gelderblom HR, Haussmann EHS, Özel M, Pauli G, Koch MA (1987) Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 156: 171–176
Gelderblom HR (1991) Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 5: 617–638
Lavalle C, Yao XJ, Ladha A, Göttlinger H, Haseltine WA, Cohen EA (1994) Requirement of the pr55gag precursor for incorporation of the vpr product into HIV type 1 viral particles. J Virol 68: 1926–1934
Göttlinger HG, Dorfman T, Cohen E, Haseltine WA (1993) Vpu protein of human immuno-deficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 90: 7381–7385
Paxton W, Connor RI, Landau NR (1993) Incorporation of vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 67: 7229–7237
Höglund S, Ohagen A, Lawrence K, Gabuzda D (1994) The role of vif during packing the core of HIV-1. Virology 201: 349–355
Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber ET, Selk LM, Clawson L, Schneider J, Kent SB (1989) Conserved folding in the retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245: 616–621
Oroszlan S, Luftig RB (1990) Retroviral proteinases. Curr Top Microbiol Immunol 157: 153–185
Haseltine WA (1991) Molecular biology of the human immunodeficiency virus type 1. FASEB J 5: 2349–2360
Nutt RF, Brady SF, Darke PL, Ciccarone TM, Colton CD, Nutt EM, Rodkey JA, Bennet CD, Waxman LH, Sigal IS (1988) Chemical synthesis and enzymatic activity of a 99 residue peptide with a sequence proposed for the HIV-1 protease. Proc Natl Acad Sci USA 85: 7129–7133
Oswald M, Helm K von der (1991) Fibronectin as a non-viral substrate for the HIV proteinase. FEBS Lett 292: 298–300
Wang CT, Barklis E (1993) Assembly, processing, and infectivity of human immunodeficiency virus type 1 mutants. J Virol 67: 4264–4273
Tritch RJ, Cheng YSE, Yin HF, Erickson-Vitanen S (1991) Mutagenesis of protease sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol 65: 922–930
Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, Venkatesan S (1988) The gag-gene products of HIV-1: alignment within the gag open reading frame, identification of posttranslational modifications and evidence for alternative gag precursors. J Virol 62: 3993–4002
Ehrlich LS, Agresta BE, Carter CA (1992) Assembly of recombinant HIV-1 capsid proteins in vitro. J Virol 66: 4874–4883
Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA (1991) Effects of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 88: 3195–3199
Höglund S, Öferstadt L-G, Nilson A, Özel M, Winkel T, Skoglund U, Gelderblom HR (1991) Analysis of the assembly of the HIV-core electron microscope tomography. In: Pearl LE (ed) Retroviral proteases control of maturation and morphogenesis. Macmillan Press, London, pp 149–157
Smith AJ, Cho MJ, Hammarskjold ML, Rekosh D (1990) Human immunodeficiency virus type 1 pr55gag and pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus like particles. J Virol 60: 2743–2750
Mergener K, Fäcke M, Walter R, Brinkmann V, Gelderblom HR, Kräusslich GH (1992) Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186: 25–39
Vernon SK, Murthy S, Wilhelm J, Chanda PK, Kalyan N, Lee S-G, Hung PP (1991) Ultrastructural characterization of human immunodeficiency virus type 1 gag-containing particles assembled in a recombinant adenovirus vectorsystem. J Gen Virol 72: 1243–1251
Karacostes V, Nagashima K, Gonda MA, Moss B (1989) Human immunodeficiency virus-like particles produced by a vaccinia virus vector. Proc Natl Acad Sci USA 86: 8964–8967
Haffar O, Ganigues J, Travis B, Moran P, Zarling J, Hu SL (1990) Human immunodeficiency virus-like nonreplicating particles assemble in a recombinant vaccinia virus expression system. J Virol 64: 2653–2659
Wagner R, Fließbach H, Modrow S, Brunn A von, Wolf H, Böltz T, Gelderblom H (1991) Expression of autologous pr55 and pr55/gp120-V3 core particles: a new approach to new vaccines including prevention of AIDS. In: Chanock RM et al. (eds) Vaccines 91. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp 109–114
Royer M, Cerutti M, Gay B, Hong SS, Deranchelle G, Boulanger P (1991) Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology 184: 417–422
Wagner R, Fließbach H, Wanner G, Motz M, Niedrig M, Deby G, Brunn A von, Wolf H (1992) Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol 127: 139–152
Fäcke M, Janetzko A, Shoeman RL, Kräusslich H-G (1993) A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol 67: 4972–4980
Wagner R, Deml L, Fließbach H, Wanner G, Wolf H (1994) Assembly and extracellular release of chimeric HIV-1 pr55gag retrovirus-like particles. Virology 200: 162–175
Wagner R, Böltz T, Deml L, Modrow S, Wolf H (1993) Induction of cytolytic T-lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinic viruses. J Gen Virol 74: 1261–1269
Poblotzki A von, Wagner R, Niedrig M, Wanner G, Wolf H, Modrow S (1993) Identification of a region in the pr55gag-polyprotein essential for HIV-1 particle formation. Virology 193: 981–985
Wills JW, Craven RC (1991) Form, function and use of retroviral gag proteins (editorial). AIDS 5: 639–654
Niedrig M, Gelderblom HR, Pauli G, März J, Bickhard H, Wolf H, Modrow S (1994) Inhibition of infectious human immunodeficiency virus type 1 particle formation by gag protein-derived peptides. J Gen Virol 75: 1469–1474
Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal JS, Darke PL, Springer JP (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus type 1. Nature 337: 615–620
Schätzl H, Gelderblom HR, Nitschko H, Helm K von der (1991) Analysis of non-infectious HIV particles produced in the presence of HIV proteinase inhibitors. Arch Virol 5: 233–239
Kaplan AH, Zack JA, Knigge M, Paul DA, Kempf DJ, Norbeck DW, Swanstrom R (1993) Partial inhibition of the human immunodeficiency type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 67: 4050–4055
Babe LM, Rose J, Craik CS (1992) Synthetic “interface” peptides alter dimeric assembly of the HIV-1 and 2 proteases. Protein Sci 1: 1244–1253
Johnson VA, Merril DP, Chou TC, Hirsch MS (1992) Human immunodeficiency type 1 (HIV-1) inhibitory interactions between protease inhibitor RO 31–8959 and zidovudine, 2′,3 dideoxycytidine, or recombinant interferon alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 166: 1143–1146
Fischl MA (1994) Combination antiretroviral therapy for HIV-infection. Hosp Pract (Off Ed) 29: 43–48
Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange M, Goudmit J, Larder BA (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165: 105–110
Haist S, März J, Wolf H, Modrow S (1992) Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1 infected and uninfected humans. AIDS Res Hum Retroviruses 8: 1909–1917
Land S, Beaton F, McPhee DA, Gust ID (1989) Comparison of the antigen (p24) assay and reverse transcriptase activity for detection of human immunodeficiency type 1 replication. J Clin Microbiol 27: 486–489
Niedrig M, Bickhard H, Gelderblom HR, Pauli G, Modrow S, Poblotzki A von, Wagner R, Wolf H (1993) Assembly of HIV-gag proteins: a target for antiviral therapy? In: Ginsberg HS et al. (eds) Vaccines 93, Cold Spring Harbor Press, Cold Spring Harbor, pp 209–214
Fei Y-J, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA (1994) Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368: 536–566
Park J, Morrow CD (1993) Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology 194: 843–850
Ruprecht RM, Mullaney S, Bernard LD, Gama Sosa MA, Hom RC, Finberg RW (1990) Vaccination with a live retrovirus: the nature of the protective immune response. Proc Natl Acad Sci USA 87: 5558–5562
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Modrow, S., Kattenbeck, B., von Poblotzki, A. et al. The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference. Med Microbiol Immunol 183, 177–194 (1994). https://doi.org/10.1007/BF00194171
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00194171